Publication: Cost-effectiveness analysis of defibrotide in the treatment of patients with severe veno-occlusive disease/sinusoidal obstructive syndrome with multiorgan dysfunction following hematopoietic cell transplantation in Spain.
No Thumbnail Available
Identifiers
Date
2021
Authors
Carcedo Rodriguez, David
Artola Urain, Teresa
Chinea Rodriguez, Anabelle
García Torres, Estefanía
González Vicent, Marta
Gutiérrez García, Gonzalo
Regueiro García, Alexandra
Calvo Hidalgo, Marcos
Villacampa, Alba
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
This study evaluated cost-effectiveness of defibrotide vs best supportive care (BSC) for the treatment of hepatic veno-occlusive disease/sinusoidal obstructive syndrome (VOD/SOS) with multiorgan dysfunction (MOD) post-hematopoietic cell transplantation (HCT) in Spain. A two-phase Markov model, comprising a 1-year acute phase with daily cycles and a lifetime long-term phase with annual cycles, was adapted to the Spanish setting. The model included a cohort of patients with severe VOD/SOS (defined as VOD/SOS with MOD) post-HCT. For the acute phase, efficacy and VOD/SOS-related length of stay were obtained from a phase 3 defibrotide study (NCT00358501). VOD/SOS-related hospital stays were 7.5 and 23.2 days in defibrotide-treated and BSC patients, respectively. Defibrotide-treated patients spent 30% of their stay in the intensive care unit vs 60% in BSC patients. Assumptions for the long-term phase and utility values were obtained from the literature. Costs were from the Spanish Health System perspective (€2019). Defibrotide cost was based on 25 mg/kg/day over 17.5 days, using local expert opinion. Life-years (LYs), quality-adjusted LYs (QALYs), and costs were estimated over a lifetime horizon, applying a 3% discount rate for costs and outcomes. Sensitivity analyses assessed the robustness of the results. Defibrotide produced an additional 1.214 QALYs and 1.348 LYs vs BSC, with a total cost of €33,708 more than BSC alone. However, defibrotide resulted in savings up to €16,644/patient for cost of hospital stay. Difference between costs and effective measures led to ratios of €27,757/QALY and €25,007/LY gained. Additional hospital stays had the greatest influence on base-case results. Probabilistic analysis confirmed the robustness of the deterministic results. Limitations include use of historical controls and assumptions extrapolated from the literature. This cost-effectiveness model, adapted to the Spanish setting, showed that defibrotide is a cost-effective alternative to BSC alone in patients with severe VOD/SOS post-HCT.
Description
MeSH Terms
Cost-Benefit Analysis
Fibrinolytic Agents
Hematopoietic Stem Cell Transplantation
Hepatic Veno-Occlusive Disease
Humans
Polydeoxyribonucleotides
Spain
Fibrinolytic Agents
Hematopoietic Stem Cell Transplantation
Hepatic Veno-Occlusive Disease
Humans
Polydeoxyribonucleotides
Spain
DeCS Terms
CIE Terms
Keywords
Defibrotide, E20, I00, Spain, cost-effectiveness, multiorgan dysfunction, sinusoidal obstruction syndrome, veno-occlusive disease